Ancotil 2.5g/250ml Solution for Infusion

  • Name:

    Ancotil 2.5g/250ml Solution for Infusion

  • Company:
    info
  • Active Ingredients:

    Flucytosine

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/05/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 20/5/2019

Click on this link to Download PDF directly

Mylan IRE Healthcare Limited

Mylan IRE Healthcare Limited

Company Products

Medicine NameActive Ingredients
Medicine Name ALDARA 5% CREAM Active Ingredients Imiquimod
Medicine Name Ancotil 2.5g/250ml Solution for Infusion Active Ingredients Flucytosine
Medicine Name Brufen 400mg film-coated Tablets Active Ingredients Ibuprofen
Medicine Name Brufen 600mg film-coated tablets Active Ingredients Ibuprofen
Medicine Name Brufen Paediatric 100mg/5ml Oral Suspension Active Ingredients Ibuprofen
Medicine Name Brufen Retard 800mg prolonged release tablets Active Ingredients Ibuprofen
Medicine Name Calvidin 600mg/400IU Chewable Tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Cibacen 10mg Film Coated Tablet Active Ingredients Benazepril Hydrochloride
Medicine Name Cibacen 5mg Film Coated Tablets Active Ingredients Benazepril Hydrochloride
Medicine Name Clozaril 100mg Tablets Active Ingredients Clozapine
Medicine Name Clozaril 25mg Tablets Active Ingredients Clozapine
Medicine Name Colifoam 10% w/w Rectal Foam Active Ingredients Hydrocortisone Acetate
Medicine Name Colofac 135mg Tablets Active Ingredients Mebeverine Hydochloride
Medicine Name Creon 10000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon 25000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon for Children 5000 Gastro-resistant Granules Active Ingredients Pancreatin
Medicine Name Cyklokapron 500mg Tablets Active Ingredients Tranexamic Acid
Medicine Name Dalmane 15mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Dalmane 30mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Desunin 4000IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name Desunin 800IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name DIFFLAM 3% CREAM Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM ORAL RINSE Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM SPRAY Active Ingredients Benzydamine Hydrochloride
Medicine Name Dona 1500mg Powder for Oral Solution Active Ingredients Glucosamine Sulfate, Sodium Chloride
1 - 0 of 97 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 20 May 2019 PIL

Reasons for updating

  • Change to section 3 - use in children/adolescents
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Updated on 20 May 2019 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 8 November 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 7 November 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 17 February 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 17 February 2016 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 4.3: Addition to contraindication regarding pregnancy

In section 4.4: Information regarding contraception in males and females added

In section 4.6:  Detailed text added regarding contraception, pregnancy and breast-feeding

In section 5.3: Preclinical safety data added

In section 10: The date of revision has been changed.

 

Updated on 17 February 2016 PIL

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.3: Addition to contraindication regarding pregnancy

In section 4.4: Information regarding contraception in males and females added

In section 4.6:  Detailed text added regarding contraception, pregnancy and breast-feeding

In section 5.3: Preclinical safety data added

In section 10: The date of revision has been changed.

 

Updated on 21 October 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 4.2: Sub-heading for adults and children has been added. New information for duration of treatment, liver impairment and older people has been added.

In section 4.3: Information regarding co-administration of Ancotil with antiviral nucleoside drugs has been added

In section 4.4: Information has been removed and information regarding haematological status and liver function, flucytosin serum levels and dihydropyrimidine dehydrogenase enzyme deficiency has been added.

In section 4.5: Additional information has been added

In section 4.8: Undesirable effects has been reformatted and new information has been added. Adverse reaction statement has been added.

In section 4.9: New information regarding signs, symptoms and management in overdose has been added.

In section 5.1: Pharmacotherapeutic group and ATC code added. Additional information added including antimycotic activity

In section 5.2: Information regarding absorption, distribution and elimination has been added.

In section 5.3: Preclinical safety data has been added

In section 10: The date of revision has been changed.

Updated on 21 October 2015 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.2: Sub-heading for adults and children has been added. New information for duration of treatment, liver impairment and older people has been added.

In section 4.3: Information regarding co-administration of Ancotil with antiviral nucleoside drugs has been added

In section 4.4: Information has been removed and information regarding haematological status and liver function, flucytosin serum levels and dihydropyrimidine dehydrogenase enzyme deficiency has been added.

In section 4.5: Additional information has been added

In section 4.8: Undesirable effects has been reformatted and new information has been added. Adverse reaction statement has been added.

In section 4.9: New information regarding signs, symptoms and management in overdose has been added.

In section 5.1: Pharmacotherapeutic group and ATC code added. Additional information added including antimycotic activity

In section 5.2: Information regarding absorption, distribution and elimination has been added.

In section 5.3: Preclinical safety data has been added

In section 10: The date of revision has been changed.

Updated on 11 May 2011 PIL

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

in section 6.4; the storage conditions have changed. the statement 'which should be  redissolved by heating to 80 degress C for not more than 30 minutes' has been removed.
In section10; teh date of revision has changed to May 2011

Updated on 11 May 2011 SmPC

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

in section 6.4; the storage conditions have changed. the statement 'which should be  redissolved by heating to 80 degress C for not more than 30 minutes' has been removed.
In section10; teh date of revision has changed to May 2011

Updated on 7 March 2011 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 7: the address of the MAH has changed
In section 10: The date of revision has changed to Feb 2011

Updated on 7 March 2011 PIL

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 7: the address of the MAH has changed
In section 10: The date of revision has changed to Feb 2011

Updated on 7 January 2011 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In Section 4.3; Addition of text stating that co-administration of Ancotil with antilviral nucleoside drugs is contraindicated.
In section 4.4; Warning added that severe drug toxcity is increased when Ancotil is used in individuals with deficiency in DPD
In Section 4.5: Warning that brivudine, sorivudine and analogues are ptent inhibitors of DPD
In section 10: Date of revision has changed 

Updated on 7 January 2011 PIL

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Free text change information supplied by the pharmaceutical company

In Section 4.3; Addition of text stating that co-administration of Ancotil with antilviral nucleoside drugs is contraindicated.
In section 4.4; Warning added that severe drug toxcity is increased when Ancotil is used in individuals with deficiency in DPD
In Section 4.5: Warning that brivudine, sorivudine and analogues are ptent inhibitors of DPD
In section 10: Date of revision has changed 

Updated on 3 September 2009 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 3 September 2009 PIL

Reasons for updating

  • New SPC for medicines.ie

Free text change information supplied by the pharmaceutical company

None provided